Phacilitate 2012: Invetech to present at 8th Annual Cell & Gene Therapy Forum in Washington
30 November 2011
David James, Invetech Director, Life Science and Pharmaceutical, will present at the Phacilitate Cell & Gene Therapy Forum, to be held in January 2012 in Washington, DC.
David, in conjunction with key industry leaders, will conduct a Breakfast workshop outlining Cell Therapy commercialisation and ask the critical question, "Cell therapies—are we finally closing the gap?"
The session will provide attendees with valuable insight into the exciting cell therapy industry and hear first-hand how some of the commercialization challenges are being addressed. Presenters include:
- Moderator, Dawn Driscoll, Principal, DCi Biotech
An update on the state of the cell therapy industry
- Dr Ian Harris, Senior Director, Cell Platform, Johnson & Johnson Biotechnology Center of Excellence - The drivers for automation of autologous and allogeneic cell therapy programs
- David James, Director, Invetech Pty Ltd
Addressing the manufacturing scale-up dilemma
- Dr John McMannis, Executive Vice President of Manufacturing, Mesoblast
Phacilitate provides a valuable meeting place to help drive the transition of technologies into safe, commercially-viable products. From promise to products, the event will cover cell therapy, gene therapy and tissue engineering.
For more information, or to register for the event, visit www.phacilitate.co.uk/cgt.
Day 2: Tuesday January 31st 2012 at 7.45am
Phacilitate Cell & Gene Therapy Forum
30 Jan - 1 Feb, 2012
The Grand Hyatt
Further Press Information
Alan Morris, Phone: +613 9211 7815, Fax: +613 9211 7703. Media Inquiries.